Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Fessahaye SN"'
Autor:
Coleman N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Karp D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Subbiah V; Early Phase Drug Development, Sarah Cannon Research Institute, Nashville, Tennessee, USA., Ahnert JR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wright J; National Cancer Institute (NCI), Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland, USA., Fessahaye SN; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ouyang F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Khalifa Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Houston, Texas, USA.; Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6877.
Autor:
Naing A; Departments of Investigational Cancer Therapeutics. Electronic address: anaing@mdanderson.org., Veasey-Rodrigues H; Departments of Investigational Cancer Therapeutics., Hong DS; Departments of Investigational Cancer Therapeutics., Fu S; Departments of Investigational Cancer Therapeutics., Falchook GS; Departments of Investigational Cancer Therapeutics., Wheler JJ; Departments of Investigational Cancer Therapeutics., Tsimberidou AM; Departments of Investigational Cancer Therapeutics., Wen S; Departments of Biostatistics., Fessahaye SN; Departments of Investigational Cancer Therapeutics., Golden EC; Departments of Investigational Cancer Therapeutics., Aaron J; Departments of Investigational Cancer Therapeutics., Ewer MS; Departments of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, USA., Kurzrock R; Departments of Investigational Cancer Therapeutics.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2012 Nov; Vol. 23 (11), pp. 2960-2963. Date of Electronic Publication: 2012 Jun 27.